Showing results (31-40 of 74) with videos related to
Sort By:
Pageof 8
Lung Cancer (Amsterdam, Netherlands)|April 2, 2021
Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): The pluie studyNicolas Epaillard, Jose Carlos Benitez, Teresa Gorria, et al.Respiratory Medicine|January 31, 2023
Integral mediastinal staging in patients with NON-SMALL cell lung cancer and risk factors for occult N2 diseaseCarmen M Lucena, Roberto Martin-Deleon, Marc Boada, et al.Cancer Research|August 4, 2004
An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growthLiang You, Biao He, Zhidong Xu, et al.British Journal of Clinical Pharmacology|September 2, 2018
Effect of multiple-dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatinR Donald Harvey, Noemi Reguart Aransay, Nicolas Isambert, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2002
Tyrosinase mRNA in blood of patients with melanoma treated with adjuvant interferonBegoña Mellado, Maria Del Carmen Vela, Dolors Colomer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2025
De-Escalation Strategies With Immune Checkpoint Blockers in Non-Small Cell Lung Cancer: Do We Already Have Enough Evidence?Jordi Remon, Martina Bortolot, Paolo Bironzo, et al.Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 3, 2026
ESTRO-EORTC expert guideline on target delineation and radiotherapy details for stage I-III small cell lung cancerAntonin Levy, Cécile Le Péchoux, Bjørn Grønberg, et al.Translational Lung Cancer Research|July 23, 2021
Consistency of recommendations for the diagnosis and treatment of non-small cell lung cancer: a systematic reviewZhe Zhang, Sen Yang, Yanfang Ma, et al.Clinical Lung Cancer|May 26, 2022
Rationale and Design of the Phase III KEYLYNK-012 Study of Pembrolizumab and Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Stage III Non-Small-Cell Lung CancerSalma K Jabbour, Byoung Chul Cho, Emilio Bria, et al.The Lancet Regional Health. Europe|March 13, 2024
New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across EuropeIlias Houda, Chris Dickhoff, Carin A Uyl-de Groot, et al.Pageof 8